GlycoMimetics (GLYC) Announces Design of Phase 3 Clinical Trial for GMI-1271 in R/R AML
Tweet Send to a Friend
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today its design for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate GMI-1271 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
